153 related articles for article (PubMed ID: 21211623)
1. [Non-antiarrhythmic drug therapy for the prevention of atrial fibrillation?].
Fauchier L; Zannad N; Clementy N; Pierre B; Cosnay P; Babuty D
Ann Cardiol Angeiol (Paris); 2010 Dec; 59 Suppl 1():S28-32. PubMed ID: 21211623
[TBL] [Abstract][Full Text] [Related]
2. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention.
Savelieva I; Kakouros N; Kourliouros A; Camm AJ
Europace; 2011 Mar; 13(3):308-28. PubMed ID: 21345926
[TBL] [Abstract][Full Text] [Related]
3. Non-antiarrhythmic drugs to prevent atrial fibrillation.
Moro C; Hernández-Madrid A; Matía R
Am J Cardiovasc Drugs; 2010; 10(3):165-73. PubMed ID: 20524718
[TBL] [Abstract][Full Text] [Related]
4. [Upstream therapy of atrial fibrillation in patients with heart failure].
Alboni P; Gianfranchi L; Pacchioni F
G Ital Cardiol (Rome); 2009 Sep; 10(9):566-71. PubMed ID: 19891248
[TBL] [Abstract][Full Text] [Related]
5. [Unsatisfactory results of upstream therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for the prevention of recurrent atrial fibrillation].
Disertori M; Zeni P; Quintarelli S; Bonmassari R
G Ital Cardiol (Rome); 2010 Nov; 11(11):829-34. PubMed ID: 21348320
[TBL] [Abstract][Full Text] [Related]
6. Statins and polyunsaturated fatty acids for treatment of atrial fibrillation.
Savelieva I; Camm J
Nat Clin Pract Cardiovasc Med; 2008 Jan; 5(1):30-41. PubMed ID: 18094671
[TBL] [Abstract][Full Text] [Related]
7. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention.
Savelieva I; Kakouros N; Kourliouros A; Camm AJ
Europace; 2011 May; 13(5):610-25. PubMed ID: 21515595
[TBL] [Abstract][Full Text] [Related]
8. [Upstream therapy for atrial fibrillation].
Kumagai K
Nihon Rinsho; 2013 Jan; 71(1):86-90. PubMed ID: 23631177
[TBL] [Abstract][Full Text] [Related]
9. The effects of statins and renin-angiotensin system blockers on atrial fibrillation recurrence following antral pulmonary vein isolation.
Al Chekakie MO; Akar JG; Wang F; Al Muradi H; Wu J; Santucci P; Varma N; Wilber DJ
J Cardiovasc Electrophysiol; 2007 Sep; 18(9):942-6. PubMed ID: 17593228
[TBL] [Abstract][Full Text] [Related]
10. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation.
Richter B; Derntl M; Marx M; Lercher P; Gössinger HD
Am Heart J; 2007 Jan; 153(1):113-9. PubMed ID: 17174648
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant therapy for atrial fibrillation.
Mohammed KS; Kowey PR; Musco S
Future Cardiol; 2010 Jan; 6(1):67-81. PubMed ID: 20014988
[TBL] [Abstract][Full Text] [Related]
12. Drug Insight: angiotensin-converting-enzyme inhibitors and atrial fibrillation--indications and contraindications.
Lévy S
Nat Clin Pract Cardiovasc Med; 2006 Apr; 3(4):220-5. PubMed ID: 16568131
[TBL] [Abstract][Full Text] [Related]
13. Renin-angiotensin-system modulators and the incidence of atrial fibrillation following hospitalization for coronary artery disease.
Singh JP; Kulik A; Levin R; Ellinor PT; Ruskin J; Avorn J; Choudhry NK
Europace; 2012 Sep; 14(9):1287-93. PubMed ID: 22539600
[TBL] [Abstract][Full Text] [Related]
14. Association between the use of non-antiarrhythmic drugs and postoperative atrial fibrillation.
Ozaydin M; Turker Y; Peker O; Erdogan D; Varol E; Dogan A; Ibrisim E
Int J Cardiol; 2010 Oct; 144(2):304-6. PubMed ID: 19282043
[TBL] [Abstract][Full Text] [Related]
15. Non-antiarrhythmic drugs in atrial fibrillation: a review of non-antiarrhythmic agents in prevention of atrial fibrillation.
Lally JA; Gnall EM; Seltzer J; Kowey PR
J Cardiovasc Electrophysiol; 2007 Nov; 18(11):1222-8. PubMed ID: 17553070
[TBL] [Abstract][Full Text] [Related]
16. The role of renin-angiotensin system blockade therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials.
Zhang Y; Zhang P; Mu Y; Gao M; Wang JR; Wang Y; Su LQ; Hou YL
Clin Pharmacol Ther; 2010 Oct; 88(4):521-31. PubMed ID: 20811347
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin converting enzyme inhibitor and angiotensin receptor blockade use in relation to outcomes in anticoagulated patients with atrial fibrillation.
Lip GY; Frison L; Grind M
J Intern Med; 2007 Jun; 261(6):577-86. PubMed ID: 17547713
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic prophylaxis of postoperative atrial fibrillation in patients undergoing cardiac surgery: beyond beta-blockers.
Davis EM; Packard KA; Hilleman DE
Pharmacotherapy; 2010 Jul; 30(7):749, 274e-318e. PubMed ID: 20575638
[TBL] [Abstract][Full Text] [Related]
19. Atrial fibrillation and heart failure: natural history and pharmacological treatment.
Savelieva I; John Camm A
Europace; 2004 Sep; 5 Suppl 1():S5-19. PubMed ID: 15450275
[TBL] [Abstract][Full Text] [Related]
20. Clinical update on the management of atrial fibrillation.
Danelich IM; Reed BN; Hollis IB; Cook AM; Rodgers JE
Pharmacotherapy; 2013 Apr; 33(4):422-46. PubMed ID: 23553811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
